The Fidelity Select Pharmaceutical Portfolio (MUTF: FPHAX) is what the name implies, a mutual fund made up of companies that specialize in the research, manufacture, sale or distribution of pharmaceuticals and drugs of all types.
Big pharma plays a big role in modern medicine, and despite trouble with generic competition and patent expiration there is still a lot of profit potential for the drug industry. The Fidelity Select Pharmaceutical fund offers investors a diversified play on the pharmaceutical sector to make a focused investment in the sector, while still diversifying.
Here are the specifics for the Fidelity Select Pharmaceutical Portfolio for today’s mutual fund spotlight:
Investing Strategy: The fund invests mostly in U.S. companies but will invest in foreign issuers. Nearly 99% of the fund’s assets are in common stocks, with the remainder in cash.
Expense Ratio: With a .94% expense ratio and no transaction fee, the Fidelity Select Pharmaceutical Portfolio is low to moderately priced, when compared with other funds in the category and it enjoys a Morningstar rating of four stars.
Top 5 Holdings: The top five stocks in the Fidelity Select Pharmaceutical Portfolio include Pfizer Inc. (NYSE: PFE) at 7.98%, Valeant Pharmaceuticals International, Inc. (NYSE: VRX) at 6.85%, Merck & Co, Inc. (NYSE: MRK) at 5.97%, Johnson & Johnson (NYSE: JNJ) at 4.55%, and Novo Nordisk A/S ADR (NYSE: NVO) at 4.27%.
Returns: The fund’s 12-month return of 27.3% outperformed the Dow Jones Industrial Average’s return of 17% return during the period and the S&P 500s return of 16.4%. And its 5-year return of 35.9%, was significantly better than the Dow’s 9.7% return and the S&P 500’s return of 1.5%.
Other Fund Statistics
Total Assets: $558.8 million (as of 6/10/11)
Minimum Investment: $2,500 ($500 for IRA)
Fund manager: Andrew Oh
Manager’s Tenure: Since July 2006